Keyphrases
Therapeutic Strategies
100%
FMS-like Tyrosine Kinase 3 (FLT3)
100%
Genome Analysis
100%
Second Relapse
100%
B-lymphoblastic Leukemia
100%
Treatment Options
33%
Tumor
33%
SETD2
33%
Overexpression
33%
Therapeutic Target
33%
Relapsed or Refractory
33%
Clinical Response
33%
Protein Kinase
33%
Therapeutic Intervention
33%
Novel Therapeutics
33%
Large Deletion
33%
EP300
33%
Clonal Architecture
33%
Point mutation
33%
Gene Fusion
33%
Patient-specific Therapy
33%
Salvage Therapy
33%
Sunitinib
33%
Complete Remission
33%
Stem Cell Transplantation
33%
Whole Genome
33%
Near-complete
33%
Locus-specific
33%
Transcriptome Analysis
33%
Microdeletion
33%
Integrative Analysis
33%
Refractory Disease
33%
Tumor Evolution
33%
Clinical Relapse
33%
ETV6
33%
Biological Relevance
33%
Whole Exome
33%
Unrelated Donor
33%
Transcriptomic Characterization
33%
PAX5
33%
Relapse Prevention
33%
Genome Characterization
33%
FLT3 mutation
33%
Refractory Cancer
33%
Genomic Assay
33%
IKZF1
33%
FLT3 Inhibitor
33%
Complete Molecular Response
33%
EP300-ZNF384
33%
Whole-transcriptome RNA-seq
33%
Biochemistry, Genetics and Molecular Biology
Genomics
100%
EP300
66%
Transcriptome
66%
SETD2
33%
Gene Expression Profiling
33%
Protein Kinases
33%
Exome
33%
Point Mutation
33%
Gene Fusion
33%
RNA Sequencing
33%
Stem Cell Transplantation
33%
ETV6
33%
PAX5
33%
IKZF1
33%
Sunitinib
33%